secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch Health Companies Inc. (BHC)
CIK:        0000885590
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001193125-23-229770
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets
--------------------------------------------------------------------------------

- Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.
- Acquired assets generated $487M net revenue in 2022 and $468M in 2021.
- Acquisition expected to close at or around end of September 2023, subject to conditions.
- Audited and unaudited abbreviated financial statements of acquired assets furnished as exhibits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/0001193125-23-229770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/d547838d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-229770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer